| Bioactivity | AZD-2207 is a cannabinoid receptor CB1 antagonist, known for its high lipophilicity. AZD-2207 has good intestinal permeability in the Caco-2 model and can be used in research related to type 2 diabetes and obesity[1]. |
| CAS | 866598-45-0 |
| Formula | C25H25Cl2F3N4O4S |
| Molar Mass | 605.46 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Christer Tannergren, et al. Biopharmaceutic Profiling of Salts to Improve Absorption of Poorly Soluble Basic Drugs. J Pharm Sci. 2016 Nov;105(11):3314-3323. [2]. Jin Hee Kim, et al. Rengyolone inhibits inducible nitric oxide synthase expression and nitric oxide production by down-regulation of NF-kappaB and p38 MAP kinase activity in LPS-stimulated RAW 264.7 cells. Biochem Pharmacol. 2006 Apr 14;71(8):1198-205. |
AZD-2207
CAS: 866598-45-0 F: C25H25Cl2F3N4O4S W: 605.46
AZD-2207 is a cannabinoid receptor CB1 antagonist, known for its high lipophilicity. AZD-2207 has good intestinal permea
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.